首页> 外文期刊>Orthopedics >Gelatin Matrix Use Reduces Postoperative Bleeding After Total Knee Arthroplasty
【24h】

Gelatin Matrix Use Reduces Postoperative Bleeding After Total Knee Arthroplasty

机译:使用明胶基质可减少全膝关节置换术后的出血

获取原文
获取原文并翻译 | 示例
           

摘要

Bleeding after total knee arthroplasty can result in significant morbidity and increases the need for blood transfusion. The proper use of intraoperative adjunctive topical hemostatic agents can enhance hemostasis perioperatively, potentially reducing blood transfusions. In this prospective study, 157 consecutive patients undergoing primary total knee arthroplasty received FLOSEAL (FLOSEAL Hemostatic Matrix; Baxter Healthcare Corporation, Hayward, California), a gelatin thrombin hemostatic matrix, 5 mL (74 patients) or 10 mL (83 patients). All patients received warfarin as thromboprophylaxis starting the day after surgery. Data were extracted via hospital chart review from 100 consecutive patients who underwent total knee arthroplasty and immediately preceded the FLOSEAL groups and did not receive FLOSEAL (control group). Postoperative drainage was significantly lower in the FLOSEAL 5 mL (236.9 mL) and 10 mL (120.5 mL) groups compared with the control group (430.8 mL; P<.0001 for both). The FLOSEAL 10 mL group had significantly less drainage than the FLOSEAL 5 mL group (P<. 0001). The predicted probability of transfusion in the FLOSEAL 5 mL group was not significantly different compared with the control group (6.0% vs 7.6%, P=.650). The predicted probability of transfusion was lower in the FLOSEAL 10 mL group compared with the control group (0.5% vs 5.5%; P=.004). Within the FLOSEAL 10 mL group, application of FLOSEAL either before or after tourniquet release had a similarly significant effect on drainage volume and predicted probability of blood transfusion. No differences in outcomes were observed by type of anesthesia used. No adverse events occurred related to FLOSEAL use.
机译:全膝关节置换术后出血可导致明显的发病率并增加输血的需要。术中适当使用辅助止血剂可以围手术期加强止血,可能减少输血。在这项前瞻性研究中,连续157例行原发性全膝关节置换术的患者接受了FLOSEAL(FLOSEAL止血基质; Baxter Healthcare Corporation,Hayward,加利福尼亚州),明胶凝血酶止血基质5 mL(74例)或10 mL(83例)。术后第二天开始,所有患者均接受华法林血栓预防。通过医院病历复习从连续接受全膝关节置换术且在接受FLOSEAL治疗之前,未接受FLOSEAL治疗的连续100例患者中提取数据(对照组)。与对照组相比,FLOSEAL 5 mL(236.9 mL)和10 mL(120.5 mL)组的术后引流明显低于对照组(430.8 mL;两者均P <.0001)。 FLOSEAL 10 mL组的引流明显少于FLOSEAL 5 mL组(P <.0001)。与对照组相比,FLOSEAL 5 mL组的预期输血可能性没有显着差异(6.0%比7.6%,P = .650)。与对照组相比,FLOSEAL 10 mL组的预期输血可能性更低(0.5%比5.5%; P = .004)。在FLOSEAL 10 mL组中,在释放止血带之前或之后应用FLOSEAL对引流量和预测的输血可能性具有相似的显着影响。所用麻醉类型未观察到预后差异。没有发生与FLOSEAL使用相关的不良事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号